search
Back to results

Introduction of Cholera Vaccine in Bangladesh (ICVB)

Primary Purpose

Cholera

Status
Completed
Phase
Not Applicable
Locations
Bangladesh
Study Type
Interventional
Intervention
ShanChol
Vaccine and behaviour
Sponsored by
International Centre for Diarrhoeal Disease Research, Bangladesh
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Cholera focused on measuring Cholera vaccine, Behaviour change intervention, Cost effectiveness and cost-benefit, Prevention of cholera, Control of Cholera, Vaccination

Eligibility Criteria

1 Year - undefined (Child, Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Apparently healthy residents of selected vaccination sites
  2. Aged 1 year and above
  3. Non-pregnant women
  4. Written informed consent

Exclusion Criteria:

  1. Age less than 1 year
  2. Pregnant women

Sites / Locations

  • International Centre for Diarrhoeal Disease Research, Bangladesh

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Active Comparator

No Intervention

Arm Label

Vaccine arm

Vaccine plus hygiene and safe water arm

Non-intervention arm

Arm Description

Thirty clusters (approximately 80,000 people) will receive cholera vaccine alone

Thirty clusters (approximately 80,000 people)will receive both cholera vaccine and behaviour change

30 neighbourhoods(approximately 80,000 people) will continue their standard habits and practices

Outcomes

Primary Outcome Measures

Number of individuals vaccinated with two dose of oral cholera vaccine.
Tergated individuals will be vaccinated and vaccination records will give the coverage.
Decrease number of cholera cases in intervention arm compared to non-intervention arm.
The primary analyses will be comparison of the incidence of primary outcome in the intervention clusters compared to the non-intervention cluster

Secondary Outcome Measures

Incidence of cholera among vaccinated individuals in vaccination area.
Vaccine-induced protective immunity will be estimated from comparing the incidence of cholera among vaccine recipients in the vaccination area and the incidence of cholera among vaccine non-recipients in the same area.
Incidence of cholera among non-vaccinated individuals in vaccination area.
Indirect protection (herd protection), the protection of non-vaccinated persons due to reduced transmission of an infection, will be estimated from comparing the incidence of cholera among non-vaccinees in the vaccination area and the incidence of cholera in the control area.
Incidence of cholera in the combined cholera vaccine and behavior change intervention area
Assessment of the impact of the combined cholera vaccine and behavior change intervention on the incidence of all diarrheas treated at the ICDDRB and other health facilities.

Full Information

First Posted
April 1, 2011
Last Updated
March 5, 2017
Sponsor
International Centre for Diarrhoeal Disease Research, Bangladesh
Collaborators
Bill and Melinda Gates Foundation, Directorate General of Health Services, Ministry of Health and Family Welfare, Bangladesh, International Vaccine Institute, Dhaka City Corporation, Ministry of Local Government and Rural Development, Bangladesh, School of Public Health and Health Professions, University at Buffalo, USA, Johns Hopkins Bloomberg School of Public Health, University of Maryland
search

1. Study Identification

Unique Protocol Identification Number
NCT01339845
Brief Title
Introduction of Cholera Vaccine in Bangladesh
Acronym
ICVB
Official Title
Introduction of Cholera Vaccine in Bangladesh: " Impact Evaluation of Cholera Vaccine and Behaviour Change Interventions in Urban Dhaka"
Study Type
Interventional

2. Study Status

Record Verification Date
February 2017
Overall Recruitment Status
Completed
Study Start Date
September 2009 (undefined)
Primary Completion Date
December 2016 (Actual)
Study Completion Date
December 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
International Centre for Diarrhoeal Disease Research, Bangladesh
Collaborators
Bill and Melinda Gates Foundation, Directorate General of Health Services, Ministry of Health and Family Welfare, Bangladesh, International Vaccine Institute, Dhaka City Corporation, Ministry of Local Government and Rural Development, Bangladesh, School of Public Health and Health Professions, University at Buffalo, USA, Johns Hopkins Bloomberg School of Public Health, University of Maryland

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to conduct and evaluate the feasibility and effectiveness of a mass cholera vaccination program to reduce diarrhea due to Vibrio cholerae in a high incidence urban area. This study will also evaluate the feasibility of adding a household hand washing and safe drinking water promotion intervention to a cholera vaccine program and the overall impact of this combination on decreasing the incidence of diarrhea due to Vibrio cholerae.
Detailed Description
Cholera continues to be a major cause of morbidity and mortality in low income countries including Bangladesh. It is estimated that there are at least 300,000 severe cases and 1.2 million infections in people in Bangladesh each year. Deaths annually from cholera may have decreased but overall morbidity remains high. The project for "Introduction of Cholera Vaccine in Bangladesh" (ICVB) will examine the effectiveness of intervention with an oral cholera vaccine in reducing incidence of cholera in urban Dhaka, and the effectiveness of a handwashing and home water treatment behaviour change intervention in reducing diarrhea due to cholera. The proposal involves evaluation of a 2-dose regimen of an oral killed whole cell (WC) vaccine and a handwashing and home water treatment behavior change program promoting improved hygiene and home drinking water treatment in reducing dehydrating diarrhea in a low income area of Dhaka, Bangladesh. The study population will include 90 clusters (neighborhoods) in an area of high cholera incidence in Mirpur with a total study population of 240,000. Thirty clusters (approximately 80,000 people) will receive cholera vaccine alone, 30 clusters will receive both cholera vaccine and behavior change and 30 neighborhoods will continue their standard habits and practices. Surveillance for cholera and diarrhea will be carried out in all the three areas during the whole project period. Following the GIS mapping and census of the target populations, the cholera vaccine will be offered to all males and non-pregnant females aged one year and above in the vaccination areas, and an aggressive hygiene and safe water promotion program will be implemented in the 30 behavior change communication clusters. Passive surveillance for cholera will be undertaken using the two ICDDR,B diarrhea treatment facilities as well as 10 other health facilities that serve the study areas. Vaccine and other public health coverage and costs effectiveness as well cost-benefit will be measured, followed by surveillance and identical follow-up studies. The hygiene and safe water behavior change program will also be continued for 4 years. The impact of interventions will be assessed by following vaccination by directly comparing the incidence of cholera and diarrhea in the intervention communities to the incidence in the standard habits and practices communities.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cholera
Keywords
Cholera vaccine, Behaviour change intervention, Cost effectiveness and cost-benefit, Prevention of cholera, Control of Cholera, Vaccination

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
240000 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Vaccine arm
Arm Type
Active Comparator
Arm Description
Thirty clusters (approximately 80,000 people) will receive cholera vaccine alone
Arm Title
Vaccine plus hygiene and safe water arm
Arm Type
Active Comparator
Arm Description
Thirty clusters (approximately 80,000 people)will receive both cholera vaccine and behaviour change
Arm Title
Non-intervention arm
Arm Type
No Intervention
Arm Description
30 neighbourhoods(approximately 80,000 people) will continue their standard habits and practices
Intervention Type
Biological
Intervention Name(s)
ShanChol
Intervention Description
Each dose of the vaccine contains whole cell Killed inactivated V.cholerae O1 and O139 strains.Vaccine is packaged as liquid formulations in 1.5-ml doses. The vaccine is given two doses separated by a two week interval and administered orally.
Intervention Type
Behavioral
Intervention Name(s)
Vaccine and behaviour
Intervention Description
Together with vaccination the community health worker will offer a hand washing station and water treatment facilities that include both hardware and a software component. The idea of the handwashing station is to bring together with soap and water that people need for handwashing, especially for handwashing after defecation. The hardware for water treatment is a chlorine dispenser that is a reservoir which holds sodium hypochlorite and dispenses a measured dose of the dilute sodium hypochlorite into a 15 liter water tank. Community residents can collect water directly from the 15 L water tanks into their own personal water storage vessels. The community health worker will negotiate with compound residents for the development of a water treatment system.
Primary Outcome Measure Information:
Title
Number of individuals vaccinated with two dose of oral cholera vaccine.
Description
Tergated individuals will be vaccinated and vaccination records will give the coverage.
Time Frame
Six months from initiation of vaccination
Title
Decrease number of cholera cases in intervention arm compared to non-intervention arm.
Description
The primary analyses will be comparison of the incidence of primary outcome in the intervention clusters compared to the non-intervention cluster
Time Frame
Two years after completion of vaccination
Secondary Outcome Measure Information:
Title
Incidence of cholera among vaccinated individuals in vaccination area.
Description
Vaccine-induced protective immunity will be estimated from comparing the incidence of cholera among vaccine recipients in the vaccination area and the incidence of cholera among vaccine non-recipients in the same area.
Time Frame
Two years after completion of vaccination.
Title
Incidence of cholera among non-vaccinated individuals in vaccination area.
Description
Indirect protection (herd protection), the protection of non-vaccinated persons due to reduced transmission of an infection, will be estimated from comparing the incidence of cholera among non-vaccinees in the vaccination area and the incidence of cholera in the control area.
Time Frame
Two years after completion of vaccination
Title
Incidence of cholera in the combined cholera vaccine and behavior change intervention area
Description
Assessment of the impact of the combined cholera vaccine and behavior change intervention on the incidence of all diarrheas treated at the ICDDRB and other health facilities.
Time Frame
Two years after completion of vaccination

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Year
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Apparently healthy residents of selected vaccination sites Aged 1 year and above Non-pregnant women Written informed consent Exclusion Criteria: Age less than 1 year Pregnant women
Facility Information:
Facility Name
International Centre for Diarrhoeal Disease Research, Bangladesh
City
Dhaka
ZIP/Postal Code
1212
Country
Bangladesh

12. IPD Sharing Statement

Citations:
PubMed Identifier
19819004
Citation
Sur D, Lopez AL, Kanungo S, Paisley A, Manna B, Ali M, Niyogi SK, Park JK, Sarkar B, Puri MK, Kim DR, Deen JL, Holmgren J, Carbis R, Rao R, Nguyen TV, Donner A, Ganguly NK, Nair GB, Bhattacharya SK, Clemens JD. Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial. Lancet. 2009 Nov 14;374(9702):1694-702. doi: 10.1016/S0140-6736(09)61297-6. Epub 2009 Oct 8. Erratum In: Lancet. 2010 Oct 23;376(9750):1392.
Results Reference
background
PubMed Identifier
18523643
Citation
Mahalanabis D, Lopez AL, Sur D, Deen J, Manna B, Kanungo S, von Seidlein L, Carbis R, Han SH, Shin SH, Attridge S, Rao R, Holmgren J, Clemens J, Bhattacharya SK. A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India. PLoS One. 2008 Jun 4;3(6):e2323. doi: 10.1371/journal.pone.0002323.
Results Reference
background
PubMed Identifier
36130764
Citation
Kang S, Chowdhury F, Park J, Ahmed T, Tadesse BT, Islam MT, Kim DR, Im J, Aziz AB, Hoque M, Pak G, Khanam F, Ahmmed F, Liu X, Zaman K, Khan AI, Kim JH, Marks F, Qadri F, Clemens JD. Are better existing WASH practices in urban slums associated with a lower long-term risk of severe cholera? A prospective cohort study with 4 years of follow-up in Mirpur, Bangladesh. BMJ Open. 2022 Sep 21;12(9):e060858. doi: 10.1136/bmjopen-2022-060858.
Results Reference
derived
PubMed Identifier
34146473
Citation
Ali M, Qadri F, Kim DR, Islam MT, Im J, Ahmmed F, Khan AI, Zaman K, Marks F, Kim JH, Clemens JD. Effectiveness of a killed whole-cell oral cholera vaccine in Bangladesh: further follow-up of a cluster-randomised trial. Lancet Infect Dis. 2021 Oct;21(10):1407-1414. doi: 10.1016/S1473-3099(20)30781-7. Epub 2021 Jun 16.
Results Reference
derived
PubMed Identifier
33215698
Citation
Jefferson T, Del Mar CB, Dooley L, Ferroni E, Al-Ansary LA, Bawazeer GA, van Driel ML, Jones MA, Thorning S, Beller EM, Clark J, Hoffmann TC, Glasziou PP, Conly JM. Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database Syst Rev. 2020 Nov 20;11(11):CD006207. doi: 10.1002/14651858.CD006207.pub5.
Results Reference
derived
PubMed Identifier
29752024
Citation
Saha A, Hayen A, Ali M, Rosewell A, MacIntyre CR, Clemens JD, Qadri F. Socioeconomic drivers of vaccine uptake: An analysis of the data of a geographically defined cluster randomized cholera vaccine trial in Bangladesh. Vaccine. 2018 Jul 25;36(31):4742-4749. doi: 10.1016/j.vaccine.2018.04.084. Epub 2018 May 8.
Results Reference
derived
PubMed Identifier
28196715
Citation
Khan AI, Ali M, Chowdhury F, Saha A, Khan IA, Khan A, Akter A, Asaduzzaman M, Islam MT, Kabir A, You YA, Saha NC, Cravioto A, Clemens JD, Qadri F. Safety of the oral cholera vaccine in pregnancy: Retrospective findings from a subgroup following mass vaccination campaign in Dhaka, Bangladesh. Vaccine. 2017 Mar 13;35(11):1538-1543. doi: 10.1016/j.vaccine.2017.01.080. Epub 2017 Feb 11.
Results Reference
derived
PubMed Identifier
26164097
Citation
Qadri F, Ali M, Chowdhury F, Khan AI, Saha A, Khan IA, Begum YA, Bhuiyan TR, Chowdhury MI, Uddin MJ, Khan JAM, Chowdhury AI, Rahman A, Siddique SA, Asaduzzaman M, Akter A, Khan A, Ae You Y, Siddik AU, Saha NC, Kabir A, Riaz BK, Biswas SK, Begum F, Unicomb L, Luby SP, Cravioto A, Clemens JD. Feasibility and effectiveness of oral cholera vaccine in an urban endemic setting in Bangladesh: a cluster randomised open-label trial. Lancet. 2015 Oct 3;386(10001):1362-1371. doi: 10.1016/S0140-6736(15)61140-0. Epub 2015 Jul 9.
Results Reference
derived
PubMed Identifier
24161413
Citation
Khan IA, Saha A, Chowdhury F, Khan AI, Uddin MJ, Begum YA, Riaz BK, Islam S, Ali M, Luby SP, Clemens JD, Cravioto A, Qadri F. Coverage and cost of a large oral cholera vaccination program in a high-risk cholera endemic urban population in Dhaka, Bangladesh. Vaccine. 2013 Dec 9;31(51):6058-64. doi: 10.1016/j.vaccine.2013.10.021. Epub 2013 Oct 22.
Results Reference
derived

Learn more about this trial

Introduction of Cholera Vaccine in Bangladesh

We'll reach out to this number within 24 hrs